Metaxalone

Spécifications

1665-48-1Numéro CAS

216-777-6Numéro CE

5-[(3,5-dimethylphenoxy)methyl]-1,3-oxazolidin-2-oneNom IUPAC

C12H15NO3Formule chimique

221.25 g/molMasse molaire

METAXALONE; 1665-48-1; Skelaxin; Zorane; Methaxalonum; Metaxalon; Methoxolone; AHR-438; 2-Oxazolidinone, 5-[(3,5-dimethylphenoxy)methyl]-; Metaxalona; 5-[(3,5-Dimethylphenoxy)methyl]-1,3-oxazolidin-2-one; Metassalone; Metaxalonum; Flexura; 5-(3,5-Xyloloxymethyl)oxazolidin-2-one; CL 39,148; DTXSID3023269; 5-[(3,5-Xylyloxy)methyl]-2-oxazolidinone; 2-Oxazolidinone, 5-((3,5-xylyloxy)methyl)-; 5-((3,5-Dimethylphenoxy)methyl)-2-oxazolidinone; 5-((3,5-Xylyloxy)methyl)-2-oxazolidinone; NSC-170959; 1NMA9J598Y; 2-Oxazolidinone, 5-((3,5-dimethylphenoxy)methyl)-; NSC170959; DTXCID103269; 5-(3,5-dimethylphenoxymethyl)-1,3-oxazolidin-2-one; 2-Oxazolidinone, 5-[(3,5-xylyloxy)methyl]-; 5-[(3,5-Dimethylphenoxy)methyl]-2-oxazolidinone; 5-((3,5-Dimethylphenoxy)methyl)-1,3-oxazolidin-2-one; Metaxal; metaxalone tablet; RefChem:55595; 216-777-6; 5-((3,5-Dimethylphenoxy)methyl)oxazolidin-2-one; Metaxolone; Metazalone; Metazolone; Metaxalonum [Latin]; Metassalone [DCIT]; Metaxalonum [INN-Latin]; Metaxalona [INN-Spanish]; NSC 170959; 5-[(3,5-dimethylphenoxy)methyl]oxazolidin-2-one; MFCD00867700; MLS003106749; s3730; NCGC00095116-01; AHR 438; 5-(3,5-dimethylphenoxymethyl)-2-oxazolidinone; Metaxalona [Spanish]; CAS-1665-48-1; Metaxalone [USAN:INN:BAN]; HSDB 3236; SR-05000001978; EINECS 216-777-6; BRN 0884592; UNII-1NMA9J598Y; .meta.Xalone; .meta.Zalone; .meta.Zolone; .meta.Xalon; Skelaxin (TN); Metaxalone (Standard); Spectrum_001741; METAXALONE [MI]; SpecPlus_000656; Metaxalone (USP/INN); METAXALONE [INN]; Spectrum2_000548; Spectrum3_001666; Spectrum4_000612; Spectrum5_001685; METAXALONE [HSDB]; METAXALONE [USAN]; METAXALONE [VANDF]; METAXALONE [MART.]; METAXALONE [USP-RS]; METAXALONE [WHO-DD]; Oprea1_438855; SCHEMBL34908; BSPBio_003451; KBioGR_001164; KBioSS_002221; DivK1c_006752; SPECTRUM1504229; SPBio_000595; CHEBI:6797; GTPL7609; orb1225988; orb1308030; CHEMBL1079604; METAXALONE [ORANGE BOOK]; Metaxalone, >=98% (HPLC); HY-B0678R; KBio1_001696; KBio2_002221; KBio2_004789; KBio2_007357; KBio3_002671; GLXC-07875; HMS1922H07; HMS2093C22; HMS5082G05; METAXALONE [USP MONOGRAPH]; Pharmakon1600-01504229; HY-B0678; MSK11343; Tox21_111428; WLN: T5MVOTJ D1OR C1 E1; 2-Oxazolidinone,5-xylyloxy)methyl]-; CCG-39592; EBC-06028; NSC758703; AKOS009035315; Tox21_111428_1; DB00660; FD25129; FS-3218; NSC-758703; NCGC00095116-02; NCGC00095116-03; NCGC00095116-05; SMR001821638; SY052772; SBI-0052859.P002; 2-Oxazolidinone,5-dimethylphenoxy)methyl]-; DB-043656; M2578; NS00000535; 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone; C07934; D00773; EN300-119839; AB00053284_04; F079268; Q6823309; SR-05000001978-1; SR-05000001978-3; BRD-A94709349-001-02-6; BRD-A94709349-001-03-4; BRD-A94709349-001-08-3; Z106952910; 5-((3,5-dimethylphenoxy)methyl)-4,5-dihydrooxazol-2-ol; 5-[(3,5-Dimethylphenoxy)methyl]-1,3-oxazolidin-2-one #; 5-{[(3,5-dimethylphenyl)oxy]methyl}-1,3-oxazolidin-2-one; Metaxalone, United States Pharmacopeia (USP) Reference StandardSynonymes